Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current and future contrast agents.

Paul A Grayburn1

  • 1Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 75235-9047, USA.

Echocardiography (Mount Kisco, N.Y.)
|May 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Adverse Events on Costs and Length of Stay Following Transcatheter Tricuspid Valve Replacement.

Structural heart : the journal of the Heart Team·2026
Same author

Isolated secondary tricuspid regurgitation after left-sided valve surgery: impact on clinical outcomes.

Open heart·2026
Same author

Tricuspid Valve Academic Research Consortium-2 (TVARC-2): Trial Design and Endpoints

Journal of the American College of Cardiology·2026
Same author

Impaired Right Ventricular Function After Transcatheter Treatment of Tricuspid Regurgitation: Does It Matter?

JACC. Cardiovascular imaging·2026
Same author

Echocardiographic Imaging Considerations for Post-Implant Evaluation of the Transcatheter EVOQUE Tricuspid Valve Replacement System.

JACC. Cardiovascular imaging·2025
Same author

Simple Ratio to Link Atrial and Ventricular Functional Mitral Regurgitation: Is it Useful?

Circulation. Cardiovascular imaging·2025
Same journal

"A Case of Anomalous Systemic Venous Connections to Left Sided Atrium in Left Isomerism".

Echocardiography (Mount Kisco, N.Y.)·2026
Same journal

Association of Valvular Disease Progression Using Echocardiographic Findings in a Large U.S. Cohort.

Echocardiography (Mount Kisco, N.Y.)·2026
Same journal

Left Atrial Appendage Mechanical Dysfunction in De Novo Organized Left Atrial Tachyarrhythmia: A Multicenter Pre-Ablation Study.

Echocardiography (Mount Kisco, N.Y.)·2026
Same journal

Transforming Cardiac Imaging With Artificial Intelligence: Automation, Precision, and Clinical Integration in Echocardiography and Magnetic Resonance Imaging.

Echocardiography (Mount Kisco, N.Y.)·2026
Same journal

Recurrent Ischemic Stroke Caused by a Residual PFO Shunt After Surgical Repair: Three-Dimensional Transesophageal Echocardiography-Guided Localization and Transcatheter Closure.

Echocardiography (Mount Kisco, N.Y.)·2026
Same journal

Intracardiac Echocardiography Versus Transesophageal Echocardiography for Guidance of Atrial Fibrillation Ablation: A Systematic Review and Meta-Analysis of Procedural Safety and Efficacy.

Echocardiography (Mount Kisco, N.Y.)·2026
See all related articles

Newer contrast agents show promise for opacifying the left heart and myocardium via intravenous injection, improving cardiac imaging. These advanced agents overcome limitations of earlier contrast methods.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Pharmacology

Background:

  • Opacifying the left heart and myocardium for imaging traditionally required invasive injections.
  • First-generation contrast agents (e.g., agitated saline, iodinated contrast) needed direct aortic or intracoronary administration.
  • Second-generation agents (e.g., albumin-bound bubbles) allowed transpulmonary passage but often yielded suboptimal left heart imaging.

Purpose of the Study:

  • To review current and novel contrast agents for left heart and myocardial opacification.
  • To discuss the development and potential of new intravenous contrast agents.
  • To evaluate the characteristics and early clinical trial results of advanced contrast agents.

Main Methods:

  • Review of existing literature on cardiac contrast agents.

Related Experiment Videos

  • Analysis of the properties of novel contrast agents, including shell composition (albumin, surfactant, lipid, polymer) and core (fluorocarbon gases).
  • Discussion of early clinical trial data for new intravenous agents.

    • Main Results:

    • First-generation agents required invasive delivery for left heart opacification.
    • Second-generation agents had limited success in left heart imaging despite transpulmonary passage.
    • Newer agents with fluorocarbon gases in various shells demonstrate potential for effective intravenous myocardial perfusion and imaging.

    Conclusions:

    • Novel contrast agents containing fluorocarbon gases show significant promise for intravenous administration.
    • These advanced agents may overcome previous limitations, enabling better opacification of the left heart and myocardium.
    • Further clinical trials are essential to confirm the efficacy and safety of these new contrast agents.